{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T04:09:45Z","timestamp":1745986185079,"version":"3.40.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,28]]},"DOI":"10.7759\/cureus.83158","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T06:03:27Z","timestamp":1745906607000},"source":"Crossref","is-referenced-by-count":0,"title":["The Indian Experience With Nonacog Beta Pegol for the Treatment of Hemophilia B in Children and Adolescents: A Safety and Efficacy Evaluation"],"prefix":"10.7759","author":[{"given":"Nehal","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghosha","family":"Pandav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi","family":"Thanvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Solanki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipti","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Katara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-92245-5","article-title":"Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria","volume":"11","author":"Ay C","year":"2021","unstructured":"Ay C, Feistritzer C, Rettl J, Schuster G, Vavrovsky A, Perschy L, Pabinger I. Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria. Sci Rep. 2021, 11:12967. 10.1038\/s41598-021-92245-5","journal-title":"Sci Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.221093","article-title":"Hemophilia A and B: molecular and clinical similarities and differences","volume":"104","author":"Castaman G","year":"2019","unstructured":"Castaman G, Matino D. Hemophilia A and B: molecular and clinical similarities and differences. Haematologica. 2019, 104:1702-9. 10.3324\/haematol.2019.221093","journal-title":"Haematologica"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/1076029616685429","article-title":"Iranian low-dose escalating prophylaxis regimen in children with severe hemophilia A and B","volume":"24","author":"Eshghi P","year":"2018","unstructured":"Eshghi P, Sadeghi E, Tara SZ, Habibpanah B, Hantooshzadeh R. Iranian low-dose escalating prophylaxis regimen in children with severe hemophilia A and B. Clin Appl Thromb Hemost. 2018, 24:513-8. 10.1177\/1076029616685429","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12902","article-title":"Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials","volume":"22","author":"Negrier C","year":"2016","unstructured":"Negrier C, Young G, Abdul Karim F, et al.. Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials. Haemophilia. 2016, 22:507-13. 10.1111\/hae.12902","journal-title":"Haemophilia"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-573055","article-title":"Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial","volume":"124","author":"Collins PW","year":"2014","unstructured":"Collins PW, Young G, Knobe K, et al.. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014, 124:3880-6. 10.1182\/blood-2014-05-573055","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2016.02.030","article-title":"Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm\u21224)","volume":"141","author":"Young G","year":"2016","unstructured":"Young G, Collins PW, Colberg T, et al.. Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm\u21224). Thromb Res. 2016, 141:69-76. 10.1016\/j.thromres.2016.02.030","journal-title":"Thromb Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13195","article-title":"Insight into health-related quality of life of young children with haemophilia B treated with long-acting nonacog beta pegol recombinant factor IX","volume":"23","author":"Carcao M","year":"2017","unstructured":"Carcao M, Kearney S, Santagostino E, et al.. Insight into health-related quality of life of young children with haemophilia B treated with long-acting nonacog beta pegol recombinant factor IX. Haemophilia. 2017, 23:e222-4. 10.1111\/hae.13195","journal-title":"Haemophilia"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1709521","article-title":"Long-term safety and efficacy of Nonacog Beta Pegol (N9-GP) administered for at least 5 years in previously treated children with hemophilia B","volume":"120","author":"Carcao M","year":"2020","unstructured":"Carcao M, Kearney S, Lu MY, Taki M, Rubens D, Shen C, Santagostino E. Long-term safety and efficacy of Nonacog Beta Pegol (N9-GP) administered for at least 5 years in previously treated children with hemophilia B. Thromb Haemost. 2020, 120:737-46. 10.1055\/s-0040-1709521","journal-title":"Thromb Haemost"},{"key":"ref9","article-title":"Report on the Annual Global Survey 2020","year":"2021","unstructured":"Report on the Annual Global Survey 2020.  World Federation of Hemophilia, 2021."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13048","article-title":"Epidemiology & social costs of haemophilia in India","volume":"140","author":"Kar A","year":"2014","unstructured":"Kar A, Phadnis S, Dharmarajan S, Nakade J.  Epidemiology & social costs of haemophilia in India. Ind J Med Res. 2014, 140:19-31. 10.1111\/hae.13048","journal-title":"Ind J Med Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01483.x","article-title":"Disability in Indian patients with haemophilia","volume":"13","author":"Kar A","year":"2007","unstructured":"Kar A, Mirkazemi R, Singh P, Potnis-Lele M, Lohade S, Lalwani A, Saha AS. Disability in Indian patients with haemophilia. Haemophilia. 2007, 13:398-404. 10.1111\/j.1365-2516.2007.01483.x","journal-title":"Haemophilia"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12838","article-title":"A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia - a success story from a resource limited country","volume":"22","author":"Verma SP","year":"2016","unstructured":"Verma SP, Dutta TK, Mahadevan S, et al.. A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia - a success story from a resource limited country. Haemophilia. 2016, 22:342-8. 10.1111\/hae.12838","journal-title":"Haemophilia"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14649","article-title":"Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: comparison of factor product use, bleed rates and pharmacokinetics","volume":"28","author":"Nummi V","year":"2022","unstructured":"Nummi V, Lehtinen AE, Iorio A, Szanto T, Lassila R. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: comparison of factor product use, bleed rates and pharmacokinetics. Haemophilia. 2022, 28:e237-44. 10.1111\/hae.14649","journal-title":"Haemophilia"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-019-01147-0","article-title":"Low dose prophylaxis in hemophilia care","volume":"36","author":"Sidharthan N","year":"2020","unstructured":"Sidharthan N, Sudevan R. Low dose prophylaxis in hemophilia care. Indian J Hematol Blood Transfus. 2020, 36:16-25. 10.1007\/s12288-019-01147-0","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S121743","article-title":"GlycoPEGylated recombinant factor IX for hemophilia B in context","volume":"12","author":"Santagostino E","year":"2018","unstructured":"Santagostino E, Mancuso ME. GlycoPEGylated recombinant factor IX for hemophilia B in context. Drug Des Devel Ther. 2018, 12:2933-43. 10.2147\/DDDT.S121743","journal-title":"Drug Des Devel Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2023.2277497","article-title":"Cost-effectiveness analysis of low-dose prophylaxis versus on-demand treatment for moderate-to-severe hemophilia A in India","volume":"28","author":"Seth T","year":"2023","unstructured":"Seth T, Garg K, Mandal PK, Datta A, Verma S, Hanagavadi S, Thota UR. Cost-effectiveness analysis of low-dose prophylaxis versus on-demand treatment for moderate-to-severe hemophilia A in India. Hematology. 2023, 28:2277497. 10.1080\/16078454.2023.2277497","journal-title":"Hematology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13272","article-title":"Low-dose prophylaxis for children with haemophilia in a resource-limited setting in south India-a clinical audit report","volume":"23","author":"Sidharthan N","year":"2017","unstructured":"Sidharthan N, Sudevan R, Narayana Pillai V, et al.. Low-dose prophylaxis for children with haemophilia in a resource-limited setting in south India-a clinical audit report. Haemophilia. 2017, 23:e382-4. 10.1111\/hae.13272","journal-title":"Haemophilia"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12690","article-title":"The hemophilia joint health score version 2.1 validation in adult patients study: a multicenter international study","volume":"6","author":"St-Louis J","year":"2022","unstructured":"St-Louis J, Abad A, Funk S, et al.. The hemophilia joint health score version 2.1 validation in adult patients study: a multicenter international study. Res Pract Thromb Haemost. 2022, 6:e12690. 10.1002\/rth2.12690","journal-title":"Res Pract Thromb Haemost"},{"key":"ref19","unstructured":"Hemophilia Joint Health Score (HJHS). (2011). Accessed.  April 23, 2025: https:\/\/elearning.wfh.org\/resource\/hemophilia-joint-health-score-hjhs\/."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/340645-the-indian-experience-with-nonacog-beta-pegol-for-the-treatment-of-hemophilia-b-in-children-and-adolescents-a-safety-and-efficacy-evaluation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T06:03:29Z","timestamp":1745906609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/340645-the-indian-experience-with-nonacog-beta-pegol-for-the-treatment-of-hemophilia-b-in-children-and-adolescents-a-safety-and-efficacy-evaluation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.83158","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,28]]}}}